Celldex Raises $31M, Gears Up for Phase III Trial of GBM Drug
By Jennifer Boggs
Thursday, May 19, 2011
Finalizing the design for its planned pivotal trial of cancer vaccine rindopepimut (CDX-110) in glioblastoma multiforme (GBM), slated to start in the second half of this year, Celldex Therapeutics Inc. padded its balance sheet with a $31.5 million public offering.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.